Staged laparoscopic adjuvant intraperitoneal chemohyperthermia after complete resection for locally advanced colorectal or gastric cancer: a preliminary experience

Chouillard, Élie; Ata, Toufic; Jonghe, Bernard De; Maggiori, Léon; Helmy, Nada; Coscas, Yvan; Outin, Hervé

doi:10.1007/s00464-008-9946-4

Cited by 14 publications

(26 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, in the last years, once the minimally invasive approach has been widely performed in an increasing number of centers, laparoscopic HIPEC gained popularity (5,20). Initially proposed with palliative intent (30), latter for the pre-therapeutic PCI evaluation (31) and to date as part of the therapeutic protocol in unresectable lesions and refractory ascites, later on the method has been also proposed in association with laparoscopic radical resections with curative intent (32).…”

Section: Discussionmentioning

confidence: 99%

“…In the meantime each couple of catheter-thermoprobe is introduced in a special protection device in order to minimize the risk of contamination of the surrounding tissues with the chemotherapeutic agent (Figs. 4,5).…”

Section: Surgical Techniquementioning

confidence: 99%

“…Moreover, in up to 25% of cases presenting recurrent tumors, the disease will be confined to the peritoneum (1-3); due to this reason, attention was focused on finding a therapeutic option which could stop the intraabdominal evolution of the metastatic process. The efficacy of cytoreductive surgery which was widely demonstrated in cases diagnosed with peritoneal carcinomatosis from colorectal, appendicular or ovarian origin, and the common pattern of intraperitoneal spread reported in advanced stage gastric cancer encouraged surgeons worldwide to apply this therapeutic protocol in patients with peritoneal carcinomatosis originating from gastric cancer (3)(4)(5). However, it should not be omitted that the association of cytoreductive surgery and HIPEC in patients with peritoneal carcinomatosis from gastric cancer can significantly increase the postoperative morbidity, a careful selection of the patients being mandatory (6).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Laparoscopic HIPEC for Peritoneal Carcinomatosis from Gastric Cancer - Technique and Early Outcomes of Our First Cases

Bălescu¹,

Godoroja²,

Gongu³

et al. 2017

chr

View full text Add to dashboard Cite

RezumatCancerul gastric rămâne una din cele mai agresive malignităţi, fiind asociat cu rezultate terapeutice nesatisfăcătoare, în special la pacienţii cu boală avansată. Din cauza acestui aspect atenţia comunităţii medicale actuale este concentrată în a identifica un tratament mai bun, un control mai eficient al bolii şi în a îmbunătăţi ratele de supravieţuire. Odată ce beneficiile chirurgiei citoreductive în asociere cu hipertermia intraperitoneală (HIPEC) au fost demonstrate pe scală largă la pacienţii diagnosticaţi cu carcinomatoză peritoneală din origine colorectală sau ovariană, atenţia a fost axată pe posibila utilizare a acestei metode la pacienţii diagnosticaţi cu carcinomatoză peritoneală de origine gastrică. Mai mult decât atât, prin utilizarea laparoscopiei pentru efectuarea chirurgiei citoreductive (L-CRS) în asociere cu chimioterapia hipertermică intraperitoneală (L-HIPEC), se aşteaptă ca beneficiile intervenţiei chirurgicale minimal invazive (MIS) să contribuie la îmbunătăţirea rezultatelor postoperatorii. În acest mod, pacienţii beneficiază de o administrare mai rapidă a tratamentului chimioterapeutic adjuvant ori de câte ori este necesar. Scop: de a prezenta tehnica L-CRS + L-HIPEC şi rezultatele obţinute într-o serie de cazuri de doi pacienţi diagnosticaţi cu carcinomatoză peritoneală din cancerul gastric. Metodă: În toate cazurile, a fost efectuată o procedură completă de investigare, incluzând laparoscopia exploratorie pentru evaluarea Indexului de Carcinomatoză Peritoneală (PCI). Consiliul Surgical TechniqueChirurgia (2017) AbstractGastric cancer remains one of the most aggressive malignancies, being associated with very poor therapeutic outcomes, especially in the advanced disease patients. Due to this evidence, finding a better treatment, a better control and higher survival rates is the current scientific focus of the medical community. Once the benefits of cytoreductive surgery in association with intraperitoneal hyperthermy (HIPEC) have been widely demonstrated in patients presenting peritoneal carcinomatosis from colorectal or ovarian origin,attention was focused on the possible benefit of this method in patients diagnosed with peritoneal carcinomatosis with gastric origin. Moreover, using laparoscopy for the cytoreductive surgery (L-CRS) and hyperthermic intraperitoneal chemotherapy (L-HIPEC), the advantages of minimal invasive surgery (MIS) are expected to contribute to improved postoperative outcomes. In this way, the patients benefit from a faster administration of the adjuvant chemotherapeutic treatment, whenever is necessary. Aim: to present the technique of L-CRS + L-HIPEC and the early therapeutic outcomes in a case series of two patients diagnosed with peritoneal carcinomatosis from gastric cancer. Method: A complete investigational work-up including diagnostic laparoscopy to evaluate the Peritoneal Carcinomatosis Index (PCI) was fulfilled in all the cases. The institutional Tumor Board decided the therapeutic strategy: laparoscopic radical resection and HIPEC (L-CRS +L-HIPEC)...

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Surgical Techniquementioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Laparoscopic HIPEC for Peritoneal Carcinomatosis from Gastric Cancer - Technique and Early Outcomes of Our First Cases

Bălescu¹,

Godoroja²,

Gongu³

et al. 2017

chr

View full text Add to dashboard Cite

show abstract

“…In 2005, we proposed a pilot study to evaluate the feasibility, safety, and short-term outcome of laparoscopic adjuvant HIPEC in selected patients after complete resection of locally advanced colorectal or gastric cancer. The preliminary results of this study have already been published [17].…”

mentioning

confidence: 87%

Peritoneal carcinomatosis of colorectal origin: is it really an end-stage disease?

2013

View full text Add to dashboard Cite

“…Adjuvant intraperitoneal chemotherapy has been examined for the prevention of peritoneal recurrence (80 (82). A randomized control trial demonstrated that peritoneal recurrence decreased when administering postoperative intraperitoneal 5-FU chemotherapy in patients with stage II colon cancer (83).…”

Section: Adjuvant Intraperitoneal Chemotherapy To Prevent Peritoneal mentioning

confidence: 99%

Regimens of Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis from Colorectal Cancer

2018

View full text Add to dashboard Cite

Staged laparoscopic adjuvant intraperitoneal chemohyperthermia after complete resection for locally advanced colorectal or gastric cancer: a preliminary experience

Abstract: Staged laparoscopic adjuvant IPCH after open or laparoscopic resection in selected patients with colorectal or gastric cancer is feasible and reasonably safe. However, additional data are required to determine the effect on long-term survival.

Cited by 14 publications

References 34 publications

Laparoscopic HIPEC for Peritoneal Carcinomatosis from Gastric Cancer - Technique and Early Outcomes of Our First Cases

Laparoscopic HIPEC for Peritoneal Carcinomatosis from Gastric Cancer - Technique and Early Outcomes of Our First Cases

Peritoneal carcinomatosis of colorectal origin: is it really an end-stage disease?

Regimens of Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis from Colorectal Cancer

Contact Info

Product

Resources

About